WHO ICTRP trial
Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A…
JPRN-UMIN000028778 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000028778 |
|---|---|
| Public title | Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation |
| Scientific title | Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation - Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation |
| Primary sponsor | University of the Ryukyus Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | erythromelalgia |
| Interventions | The administration of lacosamide is started on 50 mg/day, the dose is increased by 50 mg/ day each week until 200 mg/day for a maintenance dose. It can be increased up to 400 mg / day without side effect. The assessment of efficacy is done… |
| Registration date | Aug 23, 2017 |
| Target size | 1 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: